Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals


Actinogen Medical (ASX:ACW) is developing a promising oral treatment for Alzheimer’s and depression and is accelerating clinical trials with new capital.

CEO Steven Gourlay, joins The Market Onlineto discuss the company’s development.

Join the discussion: See what HotCopper users are saying about Actinogen Medical Ltd and be part of the conversations that move the markets.


arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.